Dividendos de Aeterna Zentaris

Dividendo controles de criterios 0/6

Aeterna Zentaris no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.9%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-CA$13.63
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

May 10

We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Nov 12

Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Jul 15

Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Mar 29

Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

Feb 04

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de AEZS han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de AEZS han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Aeterna Zentaris vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de AEZS con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (AEZS)	n/a
Suelo de mercado 25% (CA)	1.9%
Techo de mercado 25% (CA)	6.3%
Media de la industria (Biotechs)	2.9%
Previsión de analistas en 3 años (AEZS)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de AEZS en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de AEZS en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de AEZS para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que AEZS no ha comunicado ningún pago.

Dividendos de Aeterna Zentaris

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Aeterna Zentaris Inc. Provides an Update on Its Therapeutic and Diagnostic Development Pipeline Programs and Outlined Upcoming Key Milestones

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Aeterna Zentaris Inc. Achieves Proof-Of-Concept for the Treatment of NMOSD with AIM Biologicals Program

Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (Macimorelin) for Diagnosing Adult Growth Hormone Deficiency

Aeterna Zentaris Inc. Updates on Positive Pre-Clinical Results from Aim Biologicals Development Program for the Potential Treatment of Parkinson's Disease

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

Aeterna Zentaris Inc., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Aeterna Zentaris Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Third quarter 2021 earnings released: US$0.014 loss per share (vs US$0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.15 loss in 2Q 2020)

Aeterna Zentaris Inc. Provides Update on Its Pre-Clinical and Clinical Development Programs

Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Aeterna Zentaris Inc. Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Independent Director has left the company

Aeterna Zentaris Announces the Selection of A Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.036 profit in 1Q 2020)

Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.34 loss in FY 2019)

Aeterna Zentaris Inc., Annual General Meeting, May 05, 2021

New 90-day high: CA$1.37

Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

Aeterna Zentaris Inc. Enters into an Exclusive Option Agreement to Evaluate Preclinical Potential COVID-19 Vaccine Developed at the Julius-Maximilians-University Wuerzburg

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

The Nasdaq Stock Market LLC Grants an Additional 180 Calendar-Day Period Extension to Aeterna Zentaris to Regain Compliance with Minimum Bid Price Rule

New 90-day high: CA$0.90

New 90-day high: CA$0.66

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

Aeterna Zentaris Inc. Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

New 90-day low: CA$0.39

Third quarter 2020 earnings released: US$0.02 loss per share

New 90-day low: CA$0.46

The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc

Aeterna Zentaris Inc. Announces Macimorelin Clinical Program Update

New 90-day low - CA$0.49

First half earnings released

Aeterna Zentaris Inc. has completed a Follow-on Equity Offering in the amount of $7.000001 million.

Aeterna Receives Nasdaq Warning on Minimum Price

Aeterna Zentaris Inc. has completed a Composite Units Offering in the amount of $11.999087 million.

Aeterna Zentaris Inc.(NasdaqCM:AEZS) dropped from Russell Microcap Value Index

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies